Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

References

• BakerJRRiskeBDrakeJHUS Hemophilia Treatment Center population trends 1990–2010: patient diagnoses, demographics, health services utilizationHaemophilia2013191212622845803
   PubMed Web of Science ®Google Scholar
• SoucieJMEvattBJacksonDOccurrence of hemophilia in the United States. The Hemophilia Surveillance System Project InvestigatorsAm J Hematol19985942882949840909
   PubMed Web of Science ®Google Scholar
• NilssonIMHednerUAhlbergAHaemophilia prophylaxis in SwedenActa Paediatr Scand19766521291351258628
   PubMed Web of Science ®Google Scholar
• NilssonIMBlombackMAhlbergAOur experience in Sweden with prophylaxis on haemophiliaBibl Haematol1970341111245436339
   PubMedGoogle Scholar
• PetterssonHNilssonIMHednerUNorehnKAhlbergARadiologic evaluation of prophylaxis in severe haemophiliaActa Paediatr Scand19817045655706797235
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpELofqvistTPetterssonHTwenty-five years’ experience of prophylactic treatment in severe haemophilia A and BJ Intern Med1992232125321640190
   PubMed Web of Science ®Google Scholar
• FischerKvan der BomJGMauser-BunschotenEPThe effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophiliaBlood20029972337234111895765
   PubMed Web of Science ®Google Scholar
• FischerKvan der BomJGMolhoPProphylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcomeHaemophilia20028674575212410642
   PubMed Web of Science ®Google Scholar
• HayCRProphylaxis in adults with haemophiliaHaemophilia200713Suppl s2101517685918
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJAbshireTCShapiroADProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med2007357653554417687129
   PubMed Web of Science ®Google Scholar
• CollinsPFaradjiAMorfiniMEnriquezMMSchwartzLEfficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover studyJ Thromb Haemost201081838919817995
   PubMed Web of Science ®Google Scholar
• AhnstromJBerntorpELindvallKBjörkmanSA 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophiliaHaemophilia200410668969715569163
   PubMed Web of Science ®Google Scholar
• BjörkmanSProphylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspectiveHaemophilia20039Suppl s110111012709045
   PubMed Web of Science ®Google Scholar
• BlanchetteVSShapiroADLiesnerRJPlasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJ Thromb Haemost2008681319132618503631
   PubMed Web of Science ®Google Scholar
• FischerKCollinsPBjörkmanSTrends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trialsHaemophilia201117343343821299740
   PubMed Web of Science ®Google Scholar
• TarantinoMDCollinsPWHayCRClinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia AHaemophilia200410542843715357767
   PubMed Web of Science ®Google Scholar
• ValentinoLAMamonovVHellmannAA randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A managementJ Thromb Haemost201210335936722212248
   PubMed Web of Science ®Google Scholar
• AuerswaldGThompsonAARechtMExperience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia AThromb Haemost201210761072108222476554
   PubMed Web of Science ®Google Scholar
• OldenburgJGoudemandJValentinoLPostauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practiceHaemophilia201016686687720579113
   PubMed Web of Science ®Google Scholar
• PollmannHKlamrothRVidovicNProphylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional studyAnn Hematol201392568969823324986
   PubMed Web of Science ®Google Scholar
• ShapiroADAnti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia AVasc Health Risk Manag20073555556518078007
   PubMedGoogle Scholar
• FischerKvan der BomJGMauser-BunschotenEPChanges in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathyHaemophilia20017544645211554930
   PubMed Web of Science ®Google Scholar
• FijnvandraatKPetersMten CateJWInter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levelsBr J Haematol19959124744768547097
   PubMed Web of Science ®Google Scholar
• KesslerCMGillJCWhiteGC2ndB-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover studyHaemophilia2005112849115810908
   PubMed Web of Science ®Google Scholar
• MorfiniMPharmacokinetics of factor VIII and factor IXHaemophilia20039Suppl s19410012709044
   PubMed Web of Science ®Google Scholar
• van DijkKvan der BomJGLentingPJFactor VIII half-life and clinical phenotype of severe hemophilia AHaematologica200590449449815820945
   PubMed Web of Science ®Google Scholar
• BjörkmanSBlanchetteVSFischerKAdvate Clinical Program GroupComparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoringJ Thromb Haemost20108473073620398185
   PubMed Web of Science ®Google Scholar
• CarlssonMBerntorpEBjorkmanSLindvallKPharmacokinetic dosing in prophylactic treatment of hemophilia AEur J Haematol19935142472528243614
   PubMed Web of Science ®Google Scholar
• FranchiniMMannucciPMProphylaxis for adults with haemophilia: towards a personalised approach?Blood Transfus201210212312422337279
   PubMed Web of Science ®Google Scholar
• ShapiroADKorth-BradleyJPoonMCUse of pharmacokinetics in the coagulation factor treatment of patients with haemophiliaHaemophilia200511657158216236106
   PubMed Web of Science ®Google Scholar
• KasperCKDietrichSLRapaportSIHemophilia prophylaxis with factor VIII concentrateArch Intern Med19701256100410094951928
   PubMedGoogle Scholar
• SchimpfKFischerBRothmannPHemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled studyScand J Haematol Suppl1977307980327532
   PubMedGoogle Scholar
• CollinsPWBlanchetteVSFischerKrAHF-PFM Study GroupBreak-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia AJ Thromb Haemost20097341342019143924
   PubMed Web of Science ®Google Scholar
• CollinsPWBjörkmanSFischerKFactor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimensJ Thromb Haemost20108226927519943875
   PubMed Web of Science ®Google Scholar
• LindvallKAstermarkJBjorkmanSDaily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacyHaemophilia201218685585922681244
   PubMed Web of Science ®Google Scholar
• BjörkmanSOhMSpottsGPopulation pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weightBlood2012119261261822042695
   PubMed Web of Science ®Google Scholar
• BjörkmanSLimited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia AHaemophilia201016459760520148977
   PubMed Web of Science ®Google Scholar
• BjörkmanSEvaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIIIHaemophilia2011171e239e24020731725
   PubMed Web of Science ®Google Scholar
• Bolon-LargerMChamouardVBressolleFBoulieuRA limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia ATher Drug Monit2007291202617304146
   PubMed Web of Science ®Google Scholar
• CollinsPWFischerKMorfiniMBlanchetteVSBjörkmanSImplications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophiliaHaemophilia201117121020731726
   PubMed Web of Science ®Google Scholar
• StassHDetermination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII: an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophiliaHaemophilia200612Suppl 45055
   Google Scholar
• BjorkmanSFolkessonAJonssonSPharmacokinetics and dose requirements of factor VIII over the age range 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia AEur J Clin Pharmacol2009651098999819557401
   PubMed Web of Science ®Google Scholar
• OhMBjörkmanSSchrothPUse of a population pharmacokinetic model of ADVATE In pediatric and adult patients with hemophilia A permits limited blood sampling for individual dose tailoringBlood201011621608
   Web of Science ®Google Scholar
• OhMBjörkmanSSchrothPEvaluation of a population pharmacokinetic model of a recombinant FVIII (ADVATE) in patients with hemophilia A using external dataJ Thromb Haemost20119Suppl s2 Abstract P-WE-496676
   Google Scholar
• ValentinoLCollinsPPipeSPeak FVIII levels and time spent in hemostatically effective FVIII range post-infusion correlates with improved efficacy for prophylaxis in hemophilia A: A closer look at the other end of the curvePresented at the XXIV Congress of The International Society on Thrombosis and Haemostasis June 29–July 4, 2013, Amsterdam, Netherlands Available from: http://www.eventure-online.com/eventure/publicAbstractView.do?id=217806&congressId=6839Accessed October 11, 2013
   Google Scholar
• KlamrothRPollmannHHermansCThe relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) studyHaemophilia201117341242121332888
   PubMed Web of Science ®Google Scholar
• DuncanNShapiroAYeXEpsteinJLuoMPTreatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United StatesHaemophilia201218576076522548353
   PubMed Web of Science ®Google Scholar
• GringeriAvon MackensenSAuerswaldGHealth status and health-related quality of life of children with haemophilia from six West European countries. HaemophiliaMar200410Suppl 12633
   Google Scholar
• NaraineVSRisebroughNAOhPHealth-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble techniqueHaemophilia20028211212011952846
   PubMed Web of Science ®Google Scholar
• ValentinoLGiangrandePEpsteinJXiongYItoDLi-McLeodJThe relationship between specific annual bleed rates and health outcomes among children with severe hemophilia APresented at the XXIV Congress of The International Society on Thrombosis and Haemostasis June 29–July 4, 2013 Available from: http://www.eventure-online.com/eventure/publicAbstractView.do?id=218067&congressId=6839Accessed October 11, 2013
   Google Scholar
• FunkMBSchmidtHBeckerSModified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathyHaemophilia2002829810311952844
   PubMed Web of Science ®Google Scholar
• LundinBBabynPDoriaASInternational Prophylaxis Study GroupCompatible scales for progressive and additive MRI assessments of haemophilic arthropathyHaemophilia200511210911515810912
   PubMed Web of Science ®Google Scholar
• RichardsMAltisentCBatorovaAShould prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome dataHaemophilia200713547347917880432
   PubMed Web of Science ®Google Scholar
• van DijkKFischerKvan der BomJGScheibelEIngerslevJvan den BergHMCan long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and The NetherlandsBr J Haematol2005130110711215982352
   PubMed Web of Science ®Google Scholar
• WalshCEValentinoLAFactor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practicesHaemophilia20091551014102119493018
   PubMed Web of Science ®Google Scholar